Advice
in the absence of a submission from the holder of the marketing authorisation:
tafamidis meglumine (Vyndaqel®) is not recommended for use within NHS Scotland.
Indication under review: treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment,
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice77KB (PDF)
Medicine details
- Medicine name:
- tafamidis meglumine (Vyndaqel)
- SMC ID:
- 877/13
- Indication:
- Treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 May 2013